Back to search

University of Patras

Βιοχημική και μοριακή προσέγγιση του ρόλου του υαλουρονικού οξέος και του κολλαγόνου τύπου VI σε κυτταρικές σειρές από σύνδρομο Down

Abstract

dc:description

IntroductionDown syndrome (DS), or trisomy 21, is one of the most common fetal pathologies which is characterised by a triplication of the whole or distal part of human chromosome 21. Overexpression of genes located on chromosome 21, resulted by the extra gene load, has been considered to be the central point of the pathogenesis of DS. Down syndrome is a genetic disorder and the most common cause of cognitive impairment. All individuals with DS have mild to moderate learning disabilities, distinctive facial features, and low muscle tone (hypotonia) in early infancy. DS is also often associated with heart defects, leukemia, and early-onset Alzheimer's disease. The degree to which an individual is affected by these characteristics varies from mild to severe. The mechanisms by which the excess genetic material of chromosome 21 results in the dysmorphologic features of DS are largely unknown. A reason of the specific phenotypes of the individuals could originate from a perturbation of extracellular matrix (ECM). As far as the biochemical quantity is concerned, several studies showed that alterations of the ECM, with a substantial increase in hyaluronan (HA) concentration, could be the underlying cause for the increased nuchal translucency frequently present in trisomy 21 fetuses at early gestational age. Moreover, the composition of the ECM seems critical for the development of heart defects involving endocardial cushion differentiation, in particular the atrioventricular canal, which accounts for nearly half of the congenital heart diseases, observed in DS subjects. HA is a component of the connective tissue and is present in the ECM of most vertebrate tissues. It plays an important role in several cellular events, such as proliferation, migration and adhesion, whereas it is implicated in many morphogenetic processes during vertebrate embryogenesis. HA is synthesized by enzymes called HAS (for HA synthases). HAS gene family which encodes distinct enzymes in mammals is composed of three members: HAS1, HAS2 and HAS3. HΑS2 is widely expressed during embryonic development, it is much more active than HAS1, and synthesizes high molecular weight HA. Perturbations in hyaluronan levels can lead to dramatic changes in tissue homeostasis. HA catabolism in the ECM is attributed to various hyaluronidases (HYALs), that act as one or more binding sites that anchor the growing HA polymer to the enzyme, and catalyze a ratchet-like transfer reaction that moves the growing polymer one sugar at time. There are six hyaluronidase-like genes in the human genome, three of them (HYAL1, HYAL2, HYAL3) are clustered on chromosome 3p21.3, and another two genes (HYAL4 and PH-20 / SPAM1) and one expressed pseudogene (HYALP1) are similarly clustered on chromosome 7q31.3. The main HYALs in somatic tissues are HYAL1 and HYAL2. HA, depending on its size can play different biological roles indicating a highly controlled degradation path. An alteration in its metabolism could also be involved in the pathogenesis of several defects of DS. Collagen type VI (COLVI) is a microfibrillar component of the ECM and has a ubiquitous distribution throughout connective tissues. It plays a key role in the maintenance of tissue integrity by providing a structural link between different components of connective tissues, basement membranes and cells. It has three chains, α1(VI), α2(VI) and α3(VI), and each chain contains a short triple-helical region and globular extensions at the N and C terminus. COLVI molecules associate laterally in an antiparallel fashion into dimers that are stabilized by disulfide bridges. The dimers aggregate further into tetramers that are secreted into the extracellular matrix, where they join end to end into microfibrils. COLVI is thought to participate in cell adhesion and migration through interaction with member of the integrin receptor family or the NG2 proteoglycans. The genes that encode the α1(VI) and α2(VI) chains of COLVI, are located in chromosome 21, though the gene for α3(VI) is located in chromosome 2. Abnormalities in COLVI can lead to a wide spectrum of clinical phenotypes. Overexpression of COL6A1 and COL6A2 and higher amount of COLVI has been observed in the ECM of the skin from individuals affected with trisomy 21. Thus, the extra chromosome in DS results in differences in the quantity of COLVI, altering also its physiologic properties. Moreover, COLVI monomers or individuals chains can bind to collagen type I and type III, HA and heparin. AimThe aim of this study was the evaluation of the role of HA and COLVI in normal and trisomic skin fibroblasts, in order to study the mechanisms by which the excess genetic material of chromosome 21 may results in the dysmorphologic features of DS, considering that a reason of the specific phenotypes of the individuals could originate from a perturbation of the ECM. Initially it was necessary to determine the method for the cell culture conditions and development of a method for protein extraction of COLVI from skin fibroblasts. Additionally, another important objective was to compare the gene and protein expression of COLVI and HA, and the localization of these molecules in normal and trisomic skin fibroblasts. Furthermore effect of silencing of the a2(VI) the gene expression of COLVI, HAS2 and HYAL2, in normal and trisomic fibroblasts with silencing of the a2(VI), chain in normal and trisomic skin fibroblasts, was used so as to investigate. Finally, the effect of soluble COLVI and high molecular mass HA was studied, regarding the gene and protein expression and localization of these molecules. Materials and Methods:Biologic Material: In the overall study 5 normal and 3 trisomic skin fibroblast cell lines were used. The normal cells were: Detroit 550, CHP-4, NHDF, NHSF1983, NHSF 1991 and the trisomic: Detroit 539, HSF48M, και HFS10F. The cells were cultured in DMEM medium enriched with high concentration glucose, 1% glutamine, 1% antibiotics and 10% fetal bovine serum, in a 95% humidified and 5% CO2 environment. Experiments were performed when cells reached the confluence. RNA Isolation: The isolation of RNA from normal and trisomic cells was performed with the TRIzol® Reagent of (Ιnvitrogen Life Technologies), as described in the kit (Life Technologies, Gaithersburg, MD). A DNase treatment was performed using DNase I, DNase buffer and Dnase Inactivation Reagent from Ambion (Cambridgeshare, UK), according to the protocol included in the kit. The concentration of purified RNA was determined fluorometrically using the RiboGreen® RNA Quantitation Reagent And Kit from Molecular Probes (Leiden, the Netherlands).Real-Time PCRReal-time PCR was performed by means of TaqMan technology and ABI Prism 7700 apparatus (Applied Biosystems). For these experiments, oligonucleotide primers for COL6A1, COL6A2, COL6A3, HAS2, HYAL2 and GAPDH, and TaqMan® probes were Assays-on-Demand of Applied Biosystems. PCR reaction mix contained 2.5 μl of cDNA, 12.5 μl of Universal Master Mix (Applied Biosystems), 1.25 μl of Assay-on-Demand primer and probe and 8.75 μl of nuclease-free water. For each sample, ABI PRISM 7000 Sequence Detection System (SDS) software plotted an amplification curve by relating the fluorescence signal intensity (ΔRn) to the cycle number. A relative quantitative analysis was performed, using the 2-ΔΔCt value, where Ct is the threshold cycle, ΔCt = Ct (target) – Ct (endogenous control) and ΔΔCt = ΔCt (sample) – ΔCt (calibrator). GAPDH was used as an endogenous control and the sample with the lower expression of the target was used as calibrator.siRNA:The silencing of the a2(VI) chain was performed with two different protocols: i) as described in the kit of ExGen 500 in vitro Transfection Reagent (Fermentas) and ii) as described in the kit of Human Dermal Fibroblast Nucleofector® Kit (Lonza; Cat. No. CC-2511, adherent fibroblastoid cell). The siRNAs were purchased from (Αpplied biosystems, Silencer® Select and Silencer® Pre-designed & Validated Assays, ID: s3313)Determination of COLVI protein expression:Cells were lysed in urea buffer and protein extracts were analyzed using SDS-PAGE and western blot techniques. For the identification of COLVI, antibodies against the α1(VI) / α2(VI) chains were used and electrophoresis was performed in a 6% separating gel.Determination of HA content:HA content was measured by fluorophore assisted carbohydrate electrophoresis (FACE) after specific enzymatic digestions and derivatization with 2-AMAC.Results:Method development for extraction and determination of collagen type VI from skin fibroblastsFor the study of the protein expression of COLVI, skin fibroblasts were lysed with 8M urea buffer, pH (7.5) for 16h at 4 oC and the samples were analyzed under reducing conditions with Western blotting. Additionally, the cell culture conditions for the study of gene and protein expression of COLVI and HA were determined. Cells were cultured in the presence of 10% serum, without ascorbate.Comparison of normal with trisomic skin fibroblastsCOLVI and HA protein and gene expression and localization was studied in normal and trisomic skin fibroblasts. Initially, gene expression of a1(VI), a2(VI) and a3(VI) chains, HAS2 and HYAL2 was studied with Real-Time PCR. In agreement with the results from umbilical cord tissues, higher gene expression of COL6A2 was found and consequently a higher ratio of COL6A2 / COL6A3 and HAS2 gene expression in trisomic skin fibroblasts. The protein expression of a1 / a2(VI) chains was also higher in trisomic cells. Using the FACE analysis, we demonstrated the elevated level of HA production in the trisomic cells. Immunocytochemistry revealed more intense overall staining of hyaluronan in trisomic cells whereas no difference was observed in COLVI intracellularly. Confocal microscopy showed no merged staining for collagen COLVI and HA, indicating absence of colocalization for the two molecules in normal and trisomic skin fibroblasts. HA staining was more abundant in trisomic cells forming many HA vessels intracellularly with intense staining, while the plasma membrane showed ‘cable-like’ structures between the cells. Confocal microscopy revealed a more intense staining of COLVI the trisomic cells intracellularly. Finally the extracellular microfibril formation of COLVI was more uniformely distributed in normal cells whereas in trisomic cells the fibrillar network was irregularly distributed, thicker and more densely packed.Effect of a2(VI) silencing The silencing of a2(VI) had different effects on normal and trisomic cells. There was no statistically significant differences in a1(VI) gene expression in normal skin fibroblasts whereas in trisomic it was slightly increased. There was no change of a3(VI) expression levels after silencing in normal cells, while in trisomic there was a statistically significant increase. Most importantly, the silencing of a2(VI) chain induced a slight decrease of HAS2 in normal cells and a statistically significant decrease in trisomic, suggesting a pre-transcriptional regulation of these genes. HYAL2 remaines unchanged in both types of skin fibroblasts.Effects of soluble COLVI and high molecular weight HA in normal skin fibroblastsThe presence of soluble COLVI did not induce statistically significant alteration in gene expression of COLVI, HAS2 and HYAL2 in skin fibroblasts. The presence of high molecular weight HA in the medium of the cells seemed to induce an increase in a1 / a2(VI) protein expression. It also induced an increase in HA staining of the cells, leaving the COLVI staining unaffected. The presence of COLVI in the medium of cells induced a significant increase in the HA staining whereas it did not significantly affect COLVI. The presence of culture media from trisomic skin fibroblasts increased the cell proliferation rates of normal cells and induced the staining of HA between cells. Finally the presence of high molecular weight HA was found to inhibit the COLVI microfibril formation pericellularly, with a simultaneous dramatic decrease of intracellular COLVI staining of the cells.Conclusions: In the present thesis, the role of COLVI and HA in normal and trisomic skin fibroblasts was studied for the evaluation of their role in the perturbation of the ECM in DS pathology. An extra chromosome in DS could result to differences in the quantity of collagen VI, altering also its physiologic properties. Therefore a method for COLVI protein extraction from skin fibroblast cell lines was developed, that included cell lysis with urea buffer 8M (pH 7.5) and analysis with Western blotting under reducing conditions. Normal and trisomic skin fibroblast cells were compared regarding the gene and protein expression and localization of COLVI and HA. Both COLVI and HA were elevated in trisomic skin fibroblasts. This is consistent with the findings in tissues, suggesting than skin fibroblast cell lines could serve as a model for the study of the pathology of DS. The study of the localization of COLVI and HA in normal and trisomic skin fibroblasts revealed a higher staining of both molecules in trisomic cells and moreover a different distribution pattern. HA in trisomic cells gave intense staining, vessels were accumulated intracellularly and also formed ‘cable-like’ formations between cells extracellularly COLVI microfibrils extracellularly were irregularly distributed, thicker and more densely packed. HA and COLVI in normal cells it was more widely distributed.The silencing of a2(VI) chain had different effects in normal and trisomic cells. The most striking result was the reduction of HAS2 gene in trisomic cells, which suggests a pre-transcriptional regulation of a2(VI) and HAS2 genes. However, the incubation of in normal skin fibroblasts with soluble COLVI and high molecular weight HA revealed that there is also a post-transcriptional regulation. Soluble COLVI induced an increase in HA staining in normal skin fibroblasts whereas high molecular weight HA prevented the formation of the microfibrillar network of COLVI. The interaction of HA with COLVI and the perturbation of COLVI in the ECM could explain the increase production of HA in DS and further studies for the clarification of the mechanism of interaction of these macromolecules and how they contribute to DS pathology.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Stachtea, Xanthi
  • Σταχτέα, Ξανθή

Subjects

dc:subject × 19

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/30380

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Stachtea, Xanthi; Σταχτέα, Ξανθή. Βιοχημική και μοριακή προσέγγιση του ρόλου του υαλουρονικού οξέος και του κολλαγόνου τύπου VI σε κυτταρικές σειρές από σύνδρομο Down. University of Patras, 2011. http://hdl.handle.net/10442/hedi/30380